Gustavo Della Flora Nunes, PhD, University of Colorado, Denver, CO, describes future research plans to better understand the effects of myelin loss on brain function and accelerate the development of remyelinating treatments for multiple sclerosis (MS). For instance, LL-341070, a thyromimetic prodrug shown to enhance oligodendrocyte regeneration in experimental models, is expected to enter clinical trials in patients. LL-341070 and similar drugs could also be used in other demyelinating diseases besides MS. Finally, a deeper understanding of how oligodendrocytes are involved in the symptoms present in MS and how their manipulation could help improve demyelination will be the focus of future research. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.